OVERVIEW

Diagnosis and Management of Dedifferentiated Liposarcoma: A Multidisciplinary Task Force Podcast is organized by i3 Health.

Dates Available:
November 22, 2024 - November 21, 2025

Statement of Need:
Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized disease, and anthracycline-based therapy is a standard first-line treatment for advanced disease. Numerous novel therapies are currently under investigation, including CDK4/6 inhibitors, MDM2-p53 pathway inhibitors, and immunotherapies, with the potential to transform the treatment landscape for DDLPS (Nishio et al, 2021). Due to the complex management of DDLPS, collaboration of the multidisciplinary health care team, including medical oncologists, surgical oncologists, radiation oncologists, and pathologists, is crucial. This Dedifferentiated Liposarcoma Task Force podcast will provide a consensus opinion on the optimal diagnosis, treatment, and management of this disease. It features perspectives from Task Force co-chairs Richard F. Riedel, MD, Associate Professor in the Division of Medical Oncology at Duke University Medical Center, and Candace L. Haddox, MD, Physician at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard Medical School.

Learning Objectives:
Upon completion of this activity, participants should be able to

Summarize the key clinical, histopathologic, and genomic characteristics that make dedifferentiated liposarcoma unique from other soft tissue sarcoma subtypes
Assess the benefits and limitations of current molecular testing methodologies for the characterization of soft tissue sarcomas
Appreciate the role of a multimodality approach in the management of localized dedifferentiated liposarcoma, as well as the current systemic therapy landscape for patients with advanced disease
Evaluate potential emerging therapies, including MDM2-p53 pathway inhibitors, CDK4/6 inhibitors, and immunotherapeutic approaches, for the treatment of dedifferentiated liposarcoma

Gain valuable insights into the complexities of diagnosing and managing dedifferentiated liposarcoma (DDLPS) and earn free CME credit with our latest podcast. This episode features expert guidance from Dr. Richard F. Riedel of Duke University and Dr. Candace L. Haddox of Dana-Farber Cancer Institute. Delve into the latest on identifying MDM2 and CDK4 amplification, challenges in diagnosing DDLPS, and updates on emerging therapies like CDK4/6 inhibitors and immunotherapies. Learn how a multidisciplinary approach enhances patient outcomes in this rare and aggressive soft tissue sarcoma. Listen now and advance your expertise!